Pregnanolone: Clinical Trials

17 trials of Pregnanolone, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 4 terminated, 1 active not recruiting, 1 not yet recruiting. 10 Phase 2, 4 Phase 1, 2 Phase 4, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 210Completed 6, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Terminated 1
Phase 14Completed 3, Terminated 1
Phase 42Completed 1, Terminated 1
Phase 31Terminated 1

Follow Pregnanolone: new trials by email Literature Review of Pregnanolone trials Research Report on Pregnanolone

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Allopregnanolone in Chronic Complex Traumatic Brain Injury
Placebo, Allopregnanolone - Traumatic Brain Injury (TBI)
Phase 2Not yet recruitingVA Office of Research and Development1322026-12-012026-10-19
Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.
Experiment 1: Three-day aversive conditioning, extinction, and extinction retention testing paradigm, Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer., Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm - Post Traumatic Stress Disorder
Phase 2RecruitingMassachusetts General Hospital962025-08-042025-11-05
Allopregnanolone as a Regenerative Treatment for Parkinson's Disease
Allopregnanolone - Parkinson Disease
Phase 1CompletedRoberta Brinton102024-01-122026-03-13
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
Allopregnanolone, Placebo - Alzheimer Dementia, Late Onset Alzheimer Disease
Phase 2Active not recruitingUniversity of Arizona1002023-08-152026-06-30
An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus
Brexanolone - Tinnitus
Phase 2CompletedSupernus Pharmaceuticals, Inc.102023-05-102025-09-15
Study on Allopregnanolone and Depression in Perimenopausal Women
brexanolone, placebo - Depression
Phase 4TerminatedBrigham and Women's Hospital22022-11-042026-01-22
Pharmacokinetic Study for IV Allopregnanolone
PK-1 Good Manufacturing Practices (GMP) allopregnanolone (Allo) with Dexolve in 0.9% saline for infusion manufactured by the University of California, Davis, PK-2 GMP allopregnanolone (Allo) with Dexolve in 0.9% saline for infusion manufactured by the University of California, Davis. - Pharmacokinetic Study, Post Traumatic Stress Disorder
Phase 2TerminatedBoston University112022-03-042026-06-02
A Study to Explore the Effect of Sepranolone in Tourette Syndrome
Sepranolone - Tourette Syndrome, Tourette Syndrome in Adolescence
Phase 2CompletedAsarina Pharma262022-02-162023-06-09
A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting
ZULRESSO® - Postpartum Depression
Phase 4CompletedSupernus Pharmaceuticals, Inc.522021-10-082025-09-15
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
Brexanolone, Placebo - Acute Respiratory Distress Syndrome, COVID-19
Phase 3TerminatedSage Therapeutics292020-12-182022-08-19
Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study
Allopregnanolone - Alzheimer Dementia
Phase 1TerminatedUniversity of Arizona62019-10-012026-03-13
A Study Investigating the Efficacy and Safety of Sepranolone in Women With Menstrual Migraine
Sepranolone injection low dose, Sepranolone injection high dose, Placebo injection - Menstrual Migraine
Phase 2CompletedAsarina Pharma862019-08-272021-07-26
Effect of Allopregnanolone on Stress-induced Craving
Allopregnanolone, Placebos - Alcohol Use Disorder
Phase 1CompletedYale University102019-07-012025-08-22
A Study of Efficacy and Safety of Sepranolone (UC1010) in Patients With Premenstrual Dysphoric Disorder (PMDD)
Sepranolone (UC1010) low dose, Sepranolone (UC1010) high dose, Placebo - Premenstrual Dysphoric Disorder
Phase 2CompletedAsarina Pharma4752018-04-202020-10-28
Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone
Allopregnanolone - Fragile X-associated Tremor/Ataxia Syndrome
Phase 2CompletedRandi J. Hagerman, MD62015-10-012018-12-06
Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD
Allopregnanolone injection (intravenous solution), Placebo injection (intravenous solution) - Mild Cognitive Impairment, Alzheimer Disease
Phase 1CompletedUniversity of Southern California242014-08-012019-07-05
Allopregnanolone for the Treatment of Traumatic Brain Injury
Allopregnanolone injection, Placebo injection - Traumatic Brain Injury, Posttraumatic Epilepsy
Phase 2CompletedMichael A. Rogawski, MD, PhD132013-04-012017-06-28

Conditions studied

Alzheimer Disease (3)  ·  Brain Injuries, Traumatic (2)  ·  Cognitive Dysfunction (2)  ·  Dementia (2)  ·  Depression (2)  ·  Stress Disorders, Post-Traumatic (2)  ·  Alcoholism (1)  ·  Brain Injuries (1)  ·  COVID-19 (1)  ·  Depression, Postpartum (1)  ·  Epilepsy (1)  ·  Epilepsy, Post-Traumatic (1)  ·  Fragile X Tremor Ataxia Syndrome (1)  ·  Neurodegenerative Diseases (1)  ·  Pain (1)

Sponsors

Asarina Pharma (3)  ·  Supernus Pharmaceuticals, Inc. (2)  ·  University of Arizona (2)  ·  Boston University (1)  ·  Brigham and Women's Hospital (1)  ·  Massachusetts General Hospital (1)  ·  Michael A. Rogawski, MD, PhD (1)  ·  Randi J. Hagerman, MD (1)  ·  Roberta Brinton (1)  ·  Sage Therapeutics (1)  ·  University of Southern California (1)  ·  VA Office of Research and Development (1)  ·  Yale University (1)

Countries

United States (14)  ·  Sweden (2)  ·  Denmark (1)  ·  Finland (1)  ·  Germany (1)  ·  Poland (1)  ·  United Kingdom (1)

Top investigators

Roberta D Brinton, PhD (3)  ·  Gerson D Hernandez, MD, MPH (2)  ·  Ann M Rasmusson, MD (1)  ·  Christine E. Marx, MD MA (1)  ·  Elizabeth Ralevski, PhD (1)  ·  JoAnne E Natale, MD, PhD (1)  ·  Lon S Schneider, M.D. (1)  ·  Lon S Schneider, MD, MS (1)  ·  Lon Schneider, MD (1)  ·  Michael A Rogawski, MD, PhD (1)  ·  Nanette Debes, MD (1)  ·  Randi J Hagerman, MD (1)  ·  Roberta D Brinton, Ph.D. (1)  ·  Scott Sherman, MD (1)  ·  Shaughn O'Brien, MD (1)

Results publications

PMID 33344752, PMID 41341514

NIH funding

R01MH122867 (2), 1UF1AG046148 (1), I01RX002798 (1), R01AG063826 (1), R21AA024917 (1)